Mitochondrial reactive oxygen species are activated by mGluR5 through IP3 and activate ERK and PKA to increase excitability of amygdala neurons and pain behavior.
Reactive oxygen species (ROS) such as superoxide are emerging as important signaling molecules in physiological plasticity but also in peripheral and spinal cord pain pathology. Underlying mechanisms and pain-related ROS signaling in the brain remain to be determined. Neuroplasticity in the amygdala plays a key role in emotional-affective pain responses and depends on group I metabotropic glutamate receptors (mGluRs) and protein kinases. Using patch-clamp, live-cell imaging, and behavioral assays, we tested the hypothesis that mitochondrial ROS links group I mGluRs to protein kinase activation to increase neuronal excitability and pain behavior. Agonists for mGluR1/5 (DHPG) or mGluR5 (CHPG) increased neuronal excitability of neurons in the laterocapsular division of the central nucleus of the amygdala (CeLC). DHPG effects were inhibited by an mGluR5 antagonist (MTEP), IP(3) receptor blocker (xestospongin C), or ROS scavengers (PBN, tempol), but not by an mGluR1 antagonist (LY367385) or NO synthase inhibitor (l-NAME). Tempol inhibited the effects of IP(3) but not those of a PKC activator, indicating that ROS activation was IP(3) mediated. Live-cell imaging in CeLC-containing brain slices directly showed DHPG-induced and synaptically evoked mitochondrial superoxide production. DHPG also increased pain-related vocalizations and spinal reflexes through a mechanism that required mGluR5, IP(3), and ROS. Combined application of inhibitors of ERK (U0126) and PKA (KT5720) was necessary to block completely the excitatory effects of a ROS donor (tBOOH). A PKC inhibitor (GF109203X) had no effect. Antagonists and inhibitors alone did not affect neuronal excitability. The results suggest an important role for the novel mGluR5- IP(3)-ROS-ERK/PKA signaling pathway in amygdala pain mechanisms.
Department of Neuroscience and Cell Biology, University of Texas Medical Branch, Galveston, Texas 77555-1069, USA.
Zhen
Z
Li
Guangchen
G
Ji
Volker
V
Neugebauer
D000679:Amygdala / Q000187:drug effects / Q000502:physiology*; D000704:Analysis of Variance; D000818:Animals; D000975:Antioxidants / Q000494:pharmacology; D001565:Benzoates / Q000494:pharmacology; D017868:Cyclic AMP-Dependent Protein Kinases / Q000378:metabolism*; D003497:Cyclic N-Oxides / Q000494:pharmacology; D004791:Enzyme Inhibitors / Q000494:pharmacology; D018691:Excitatory Amino Acid Antagonists; D048049:Extracellular Signal-Regulated MAP Kinases / Q000378:metabolism*; D005998:Glycine / Q000031:analogs & derivatives / Q000494:pharmacology; D015544:Inositol 1,4,5-Trisphosphate / Q000378:metabolism*; D047028:Macrocyclic Compounds / Q000494:pharmacology; D008928:Mitochondria / Q000187:drug effects / Q000378:metabolism*; D019331:NG-Nitroarginine Methyl Ester / Q000494:pharmacology; D009474:Neurons / Q000187:drug effects / Q000502:physiology*; D010080:Oxazoles / Q000494:pharmacology; D010146:Pain / Q000378:metabolism / Q000503:physiopathology*; D010147:Pain Measurement / Q000187:drug effects; D058748:Pain Perception / Q000187:drug effects / Q000502:physiology; D018408:Patch-Clamp Techniques; D011725:Pyridines / Q000494:pharmacology; D017382:Reactive Oxygen Species / Q000378:metabolism*; D064529:Receptor, Metabotropic Glutamate 5; D018094:Receptors, Metabotropic Glutamate / Q000819:agonists / Q000378:metabolism*; D015398:Signal Transduction / Q000502:physiology; D013113:Spin Labels; D013481:Superoxides / Q000378:metabolism; D013844:Thiazoles / Q000494:pharmacology; D014828:Vocalization, Animal / Q000187:drug effects / Q000502:physiology
C472365:3-((2-methyl-1,3-thiazol-4-yl)ethynyl)pyridine; D000975:Antioxidants; D001565:Benzoates; D003497:Cyclic N-Oxides; D004791:Enzyme Inhibitors; D018691:Excitatory Amino Acid Antagonists; D047028:Macrocyclic Compounds; D010080:Oxazoles; D011725:Pyridines; D017382:Reactive Oxygen Species; D064529:Receptor, Metabotropic Glutamate 5; D018094:Receptors, Metabotropic Glutamate; D013113:Spin Labels; D013844:Thiazoles; C511704:xestospongin C; D013481:Superoxides; C079694:alpha-methyl-4-carboxyphenylglycine; D015544:Inositol 1,4,5-Trisphosphate; D017868:Cyclic AMP-Dependent Protein Kinases; D048049:Extracellular Signal-Regulated MAP Kinases; D005998:Glycine; C001803:tempol; D019331:NG-Nitroarginine Methyl Ester
J Neurosci Res. 2002 Oct 1;70(1):1-7
12237859
Front Neurosci. 2009 Sep 15;3(2):175-81
20011139
J Neurosci. 2007 Feb 14;27(7):1543-51
17301163
J Biol Chem. 2008 May 16;283(20):13506-9
18364356
Cell Mol Life Sci. 2000 Aug;57(8-9):1287-305
11028919
Science. 2009 Aug 7;325(5941):760-4
19661434
J Neurophysiol. 2010 Jan;103(1):382-91
19906875
J Neurophysiol. 2009 Oct;102(4):2253-64
19625541
Pain. 2009 Jan;141(1-2):135-42
19059721
Mol Pain. 2010 Feb 08;6:10
20144185
Physiol Rev. 2004 Jul;84(3):803-33
15269337
Neuron. 1998 Jan;20(1):143-51
9459450
Int J Dev Neurosci. 1993 Jun;11(3):357-68
7689287
Curr Drug Targets CNS Neurol Disord. 2002 Jun;1(3):283-96
12769620
Neuron. 2005 Oct 20;48(2):175-87
16242399
Mol Interv. 2004 Oct;4(5):248-50
15471906
Br J Pharmacol. 2002 Apr;135(8):1959-66
11959799
Brain Res Rev. 2009 Apr;60(1):226-42
19162070
J Neurosci. 2008 Apr 9;28(15):3861-76
18400885
J Biol Chem. 1998 Jul 17;273(29):18623-32
9660836
J Physiol. 2005 May 1;564(Pt 3):907-21
15760935
Am J Physiol Gastrointest Liver Physiol. 2010 Feb;298(2):G295-303
19875699
Brain Res Bull. 1994;33(5):529-34
8186998
J Neurosci. 2005 Nov 16;25(46):10717-28
16291945
Cell Calcium. 2007 May;41(5):491-502
17074386
J Comp Neurol. 1988 Apr 15;270(3):416-26, 398-9
2836477
J Neurophysiol. 2004 Jan;91(1):13-24
13679408
FEBS J. 2006 Feb;273(3):433-50
16420469
J Neurosci. 2009 Jan 7;29(1):159-68
19129394
J Neurosci. 2006 Apr 12;26(15):3933-41
16611809
Neuroreport. 2009 Oct 28;20(16):1424-8
19794317
Exp Neurol. 2009 Mar;216(1):66-74
19094988
Nat Protoc. 2008;3(6):941-7
18536642
Mol Cancer Ther. 2007 Jun;6(6):1814-22
17575110
Behav Brain Res. 2007 Jul 19;181(1):163-7
17481745
J Neurosci Methods. 1980 Dec;3(2):129-49
6110810
Pain. 2007 Dec 15;133(1-3):9-17
17379413
J Neurosci. 2010 Apr 14;30(15):5451-64
20392966
J Neurosci Res. 2007 Sep;85(12):2770-7
17265464
J Neurosci Methods. 2005 Feb 15;141(2):261-9
15661308
Pain. 2004 Jul;110(1-2):299-309
15275780
Neuroreport. 1996 May 31;7(8):1382-4
8856680
Ann N Y Acad Sci. 2003 Nov;1003:12-21
14684432
J Neurosci. 2002 Jun 15;22(12):4860-8
12077183
Neuropharmacology. 2007 Jul;53(1):58-70
17543352
Antioxid Redox Signal. 1999 Winter;1(4):481-99
11233146
Pain. 2005 Jan;113(1-2):211-22
15621382
Neuroscientist. 2004 Jun;10(3):221-34
15155061
J Neurosci. 2007 Jun 13;27(24):6510-20
17567812
J Neurophysiol. 2008 Mar;99(3):1565-71
18199822
Pain. 2007 Oct;131(3):262-271
17317010
Antioxid Redox Signal. 2007 Feb;9(2):233-44
17115936
Neuron. 2005 Sep 15;47(6):783-6
16157273
Mol Pain. 2008 Jul 16;4:26
18631385
Int Rev Neurobiol. 2009;85:135-44
19607966
Mol Pain. 2007 Mar 28;3:8
17391515
Neurosci Lett. 2002 Sep 20;330(2):127-30
12231428
J Neurophysiol. 2010 Jul;104(1):218-29
20463194
Pain. 2008 Sep 15;138(3):514-524
18375065
Neurosci Biobehav Rev. 2004 Jan;27(8):729-37
15019423
Antioxid Redox Signal. 2008 Jul;10(7):1275-312
18377233
J Neurophysiol. 2007 Jun;97(6):3893-904
17392412
Learn Mem. 2009 Jun 24;16(7):421-5
19553379
J Neurosci. 1995 May;15(5 Pt 2):3970-81
7751958
Behav Brain Res. 2010 May 1;209(1):174-8
20097232
CNS Drug Rev. 2006 Summer;12(2):149-66
16958988
Pain. 2004 Sep;111(1-2):116-24
15327815
Cell Calcium. 2006 Nov-Dec;40(5-6):553-60
17074387
Mol Pharmacol. 2010 Jun;77(6):995-1004
20215561
J Neurosci. 2003 Jan 1;23(1):52-63
12514201
Exp Physiol. 2002 Mar;87(2):251-8
11856971
J Neurophysiol. 1998 Jul;80(1):452-7
9658063
J Neurosci. 2010 Jun 16;30(24):8203-13
20554871
Neuron. 2008 Jun 12;58(5):662-71
18549779
J Pharmacol Exp Ther. 2004 Jun;309(3):869-78
14988418
Handb Exp Pharmacol. 2007;(177):217-49
17087125
Mol Pain. 2008 Jun 23;4:24
18573207
Pain. 2007 Jan;127(1-2):17-26
16965855
J Neurophysiol. 2003 Sep;90(3):1671-9
12750419
J Neurosci. 2001 Jun 1;21(11):3771-9
11356865